Health TrialsbyHealthPanel

Liver Embolization Approaches for Tumor Management

ConditionsHepatocellular CarcinomaCholangiocarcinomaMetastatic Colon CancerMetastatic CancerMetastatic Gastric CancerPrimary Liver CancerMetastatic Pancreatic Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS San Raffaele

About this trial

The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

≥ 18 yoa

patients with patients with primary or secondary liver disease not amenable for surgery or ablation

patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy

able and willing to sign informed consent

Disqualifiers

pregnant women

patients with uncorrectable coagulopathy

diffuse extrahepatic disease

for lobar TACE and TARE - presence of bilodigestive shunt

Trial population

Patients with primary or secondary liver tumors

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Embolization

    Procedure/Surgery

    Endovascular treatment for patients with primary and secondary liver tumors

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Progression free survival

Treatment Efficacy

Time frame
Short term (3-6 months)
2

Progression free survival

Time frame
From time of intervention up to 1 year (medium term)
3

Progression free survival

Time frame
From time of intervention up to 5 years (Long term)
4

Residual hepatic volume

Treatment Efficacy

Time frame
within 40 days of procedure

Secondary outcomes

1

Overall survival

Overall survival

Time frame
From date of procedure until the date of death from any cause, whichever came first, assessed up to 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

IRCCS San Raffaele

Lead sponsor

Source ClinicalTrials.gov
Apply now